行情

ICPT

ICPT

Intercept
NASDAQ

实时行情|Nasdaq Last Sale

119.36
+4.48
+3.90%
盘后: 119.25 -0.11 -0.09% 18:15 12/11 EST
开盘
115.40
昨收
114.88
最高
119.93
最低
113.21
成交量
80.37万
成交额
--
52周最高
131.87
52周最低
56.76
市值
39.07亿
市盈率(TTM)
-10.9792
分时
5日
1月
3月
1年
5年

分析师评级

20位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ICPT 新闻

  • Genfit Hopes to Buck the Odds With NASH Drug
  • GuruFocus.com.1天前
  • Intercept Pharmaceuticals: Blockbuster Therapy Unveils An Upside Catalyst
  • Seeking Alpha - Article.1天前
  • Intercept to Host NASH Commercial Day for Investors on December 16, 2019 in New York
  • GlobeNewswire.1天前
  • Here's Why Intercept Pharmaceuticals Stock Rose 48.9% in November
  • MotleyFool.com.1天前

更多

所属板块

生物技术和医学研究
-0.34%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

ICPT 简况

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company's product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). In addition to OCA, it is developing other bile acid analog compounds targeting FXR and a second dedicated bile acid receptor called TGR5, which is a target of interest for the treatment of type 2 diabetes and other gastrointestinal indications. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.
展开

Webull提供Intercept Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。